A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: EndoTAG-1|DRUG: Paclitaxel|DRUG: Gemcitabine Hydrochloride
Sponsor: SynCore Biotechnology Co., Ltd.